Summary
Lonza: Strong H1 Execution, Higher Guidance Means Higher Upside
H1 results showed 16% sales growth, a 44% net profit increase, and EBITDA margin expansion to 34.8%, driven by higher asset utilization and segment outperformance. Integrated Biologics, Advanced Synthesis, and Specialized Modalities each delivered double-digit growth. Management raised its 2026 CORE EBITDA margin outlook to 33–34% while maintaining 11–12% sales growth guidance. Our buy rating is confirmed.
Lonza Group AG (LZAGY) Q2 2026 Earnings Call Transcript
Lonza Group AG (LZAGY) Q2 2026 Earnings Call Transcript
Lonza: Structural Growth Intact, CHI Exit Strengthens Focus, Recent Weakness Reinforces Entry Opportunity
Lonza's FY2025 results exceeded expectations, with EBITDA growth significantly ahead of revenue, supported by operating leverage and margin recovery. The CHI divestment accelerates Lonza's transition to a pure-play CDMO, improves capital allocation visibility, and supports shareholder returns through buybacks and deleveraging. Recent share price weakness appears driven by external factors, while structural tailwinds, biologics demand, onshoring, and patent cliff dynamics continue to underpin a favorable risk-reward.
Lonza Group AG Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| MA mason adams PVG ASSET MANAGEMENT Corp. | 12,004.2 | $229,304.23 | $836,572.7 | $607,268.47 | 264.83% |
Lonza Group AG (LZAGY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Lonza Group AG ever had a stock split?
Lonza Group AG Profile
| Professional Services Industry | Industrials Sector | Wolfgang Wienand CEO | OTC PINK Exchange | 54338V101 CUSIP |
| CH Country | 16,866 Employees | 13 May 2026 Last Dividend | - Last Split | - IPO Date |
Overview
Lonza Group AG, established in 1897 and headquartered in Basel, Switzerland, operates on a global scale, providing a broad spectrum of products and services to the pharmaceutical, biotech, and nutrition markets across Europe and internationally. The company is structured into four main segments: Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients. Each of these segments plays a critical role in meeting the development, manufacturing, and market needs of the company’s diverse client base, ranging from pharmaceutical giants to emerging biotech firms. With a strong focus on innovation and quality, Lonza is dedicated to advancing the science and technology that empower the healthcare and nutritional industries, contributing significantly to the development of life-saving therapies and products.
Products and Services
- Biologics
This segment is focused on the contract development and manufacturing organization (CDMO) services for biopharmaceuticals. It covers a comprehensive range of clinical and commercial manufacturing needs throughout the product lifecycle, including both drug substance and drug product manufacturing. Capabilities also extend to process development, cell line development, and analytical services, ensuring clients receive full-spectrum support for their biological drug candidates.
- Small Molecules
As an integrated development and manufacturing service provider, this segment offers extensive support for small molecule drug substances and their intermediates. Services span from early design and development through to commercial manufacturing, covering all aspects needed for the successful launch and supply of small molecule therapeutics. This includes custom synthesis, process development, scale-up, and regulatory support.
- Cell & Gene
This segment is at the forefront of cell and gene therapy manufacturing, providing technologies and platforms that streamline the production processes of these cutting-edge therapies. Lonza offers contract development and manufacturing services, along with regulatory support for a wide variety of therapies including allogeneic and autologous cell therapies, exosome-based therapies, and viral vector gene therapies. The Cocoon® Platform, a proprietary, closed, and automated system, exemplifies Lonza’s innovation in this area, offering a scalable solution for patient-scale cell therapy manufacturing. Additionally, it provides specialty raw materials and technology solutions key to the cell and gene therapy, injectable drug, vaccine, and bio-manufacturing markets.
- Capsules & Health Ingredients
This segment supplies a broad portfolio of capsules and dosage form solutions alongside health ingredients for the pharmaceutical and nutraceutical industries. With an emphasis on innovation, quality, and safety, Lonza’s offerings range from hard capsule manufacturing to the development of highly specialized dosage forms such as liquid-filled capsules and advanced delivery systems. The segment supports customers in improving bioavailability, targeted delivery, and overall product performance of their health and nutrition products.
